Trial Profile
A Phase 2 Study of Ibrutinib in Advanced Systemic Mastocytosis
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary)
- Indications Mast Cell Leukemia; Systemic mastocytosis
- Focus Therapeutic Use
- 17 Nov 2017 Status changed from recruiting to discontinued.
- 27 Jun 2017 Planned End Date changed from 1 Jun 2017 to 1 Jun 2018.
- 27 Jun 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Dec 2017.